Enhancing Genetic Task Efficiency at Volta Labs
Transforming the costs and efficiency of DNA sequencing, Volta Labs is shaking up the industry with their innovative digital microfluidic technology. Traditional sample preparation methods, like those relying on liquid-handling robots, have become a significant bottleneck due to high costs and minimal sample utilization.
Volta Labs provides an end-to-end integrated solution, offering a sleek and budget-friendly alternative to pricey liquid handling machines and manual pipetting. Their platform, based on digital microfluidic technology, allows users to manipulate droplets around a printed circuit board to automate biological reactions, from raw sample to prepared library ready for sequencing.
Co-founder and Head of Engineering, Will Langford SM '14, PhD '19, describes their technology as a low-cost, minimally consumable device that enables rapid and flexible composition of new biological workflows. Unlike cumbersome traditional liquid-handling automation systems, the Volta platform not only simplifies sample prep but also slashes costs in the space with a new consumable construction.
Volta's platform addresses the bottleneck of high-cost, error-prone traditional automation machines commonly used in the biotechnology field. By offering early-stage and mid-to-low-throughput biotech companies powerful tools, Volta aims to level the playing field and enable these companies to compete with larger players.
Further down the road, Volta's work will impact a variety of applications in synthetic biology and biopharma. Their innovation could revolutionize diagnostics, significantly reducing the use of pipette tips and almost entirely eliminating bottlenecks in the supply chain.
To achieve this innovation, Volta adopts a multidispciplinary systems perspective. As Volta Labs CEO Udayan Umapathi SM '17 explains, "We're a new type of biotechnology company." Engineering biology like engineering, he argues, is a necessity, and as more and more systems thinkers join the field, companies like Volta will lead the way.
While detailed information on the cost and efficiency comparisons between Volta Labs and traditional automation methods is not immediately available, digital microfluidic technology tends to offer advantages in terms of precision, efficiency, and sample conservation, potentially reducing costs over time. On the other hand, traditional methods can be more resource-intensive and less efficient in the long run.
With an initial investment in equipment being a potential barrier, the future of gene sequencing looks brighter and more inclusive thanks to Volta Labs. Academic labs, core facilities, and small-to-medium biotech companies will no longer need to worry about footing the bill for expensive mechanical robots. Instead, they'll have the tools to compete with larger players, ultimately benefiting the industry as a whole.
- Volta Labs' digital microfluidic technology, based on their innovative platform, automates biological reactions, potentially reducing costs in the biotech field.
- Will Langford, the co-founder and Head of Engineering at Volta Labs, describes their technology as a low-cost, minimally consumable device that can enable rapid and flexible composition of new biological workflows.
- Volta's platform could revolutionize diagnostics, significantly reducing the use of pipette tips and almost entirely eliminating bottlenecks in the supply chain, particularly in synthetic biology and biopharma applications.
- Engineering biology like engineering, Volta Labs adopts a multidisciplinary systems perspective, which could lead to further cost reductions and improved efficiency compared to traditional automation methods.
- By offering early-stage and mid-to-low-throughput biotech companies powerful tools, Volta aims to level the playing field, enabling these companies to compete with larger players and making the future of gene sequencing look brighter and more inclusive.
